{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:29:28Z","timestamp":1782962968752,"version":"3.54.5"},"reference-count":88,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T00:00:00Z","timestamp":1426809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Merck & Co. Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated with anticancer treatment that can have a significant adverse impact on patient health-related quality of life and that can potentially undermine the effectiveness of chemotherapy. Traditional regimens to prevent CINV generally involved a combination of a corticosteroid plus a 5-hydroxytryptamine (5HT3) receptor antagonist (RA). In the past 10 years, antiemetic treatment has greatly advanced with the availability of the neurokinin-1 receptor antagonist (NK1 RA) aprepitant and its prodrug fosaprepitant. NK1 RAs have a different mechanism of action in CINV than corticosteroids and 5HT3 RAs, thus their use can complement traditional antiemetic drugs and can enhance control of CINV. This review examined accumulated data regarding the safety and efficacy of aprepitant and fosaprepitant over the decade since the first regulatory approval. Data from key studies of aprepitant and fosaprepitant in the prevention of CINV in patients receiving moderately and highly emetogenic chemotherapy were explored, as were recommendations in currently available guidelines for their use. In addition, their use as antiemetic therapy in special patient populations was highlighted. Future perspectives on potential uses of aprepitant and fosaprepitant for indications other than CINV are presented.<\/jats:p>","DOI":"10.1634\/theoncologist.2014-0229","type":"journal-article","created":{"date-parts":[[2015,3,21]],"date-time":"2015-03-21T04:03:53Z","timestamp":1426910633000},"page":"450-458","source":"Crossref","is-referenced-by-count":123,"title":["Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety"],"prefix":"10.1093","volume":"20","author":[{"given":"Matti","family":"Aapro","sequence":"first","affiliation":[{"name":"Clinique de Genolier, Genolier, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Carides","sequence":"additional","affiliation":[{"name":"Temple University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo L.","family":"Rapoport","sequence":"additional","affiliation":[{"name":"The Medical Oncology Center of Rosebank, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Schmoll","sequence":"additional","affiliation":[{"name":"University Clinic Halle, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Warr","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,3,20]]},"reference":[{"key":"2021122309230723200_B1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/BF00434947","article-title":"Quality of life consequences of chemotherapy-induced emesis","volume":"1","author":"Lindley","year":"1992","journal-title":"Qual Life Res"},{"key":"2021122309230723200_B2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/BF01880641","article-title":"Impact of nausea\/vomiting on quality of life as a visual analogue scale-derived utility score","volume":"4","author":"Grunberg","year":"1996","journal-title":"Support Care Cancer"},{"key":"2021122309230723200_B3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s005200050078","article-title":"Effect of postchemotherapy nausea and vomiting on health-related quality of life","volume":"5","author":"Osoba","year":"1997","journal-title":"Support Care Cancer"},{"key":"2021122309230723200_B4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1477-7525-1-46","article-title":"Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy","volume":"1","author":"Ballatori","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"suppl 1","key":"2021122309230723200_B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198300251-00002","article-title":"Nausea and vomiting as major complications of cancer chemotherapy","volume":"25","author":"Laszlo","year":"1983","journal-title":"Drugs"},{"key":"2021122309230723200_B6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/CAD.0b013e328359d7ba","article-title":"Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: From guidelines to clinical practice in solid tumors","volume":"24","author":"Di Maio","year":"2013","journal-title":"Anticancer Drugs"},{"key":"2021122309230723200_B7","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s00520-013-1843-2","article-title":"Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting","volume":"21","author":"Molassiotis","year":"2013","journal-title":"Support Care Cancer"},{"key":"2021122309230723200_B8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/cas.12146","article-title":"Risk factors of chemotherapy-induced nausea and vomiting: Index for personalized antiemetic prophylaxis","volume":"104","author":"Sekine","year":"2013","journal-title":"Cancer Sci"},{"key":"2021122309230723200_B9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JOP.2010.000151","article-title":"Prevalence of delayed nausea and\/or vomiting in patients treated with oxaliplatin-based regimens for colorectal cancer","volume":"8","author":"Fleishman","year":"2012","journal-title":"J Oncol Pract"},{"key":"2021122309230723200_B10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","article-title":"Chemotherapy-induced nausea and vomiting: Incidence and impact on patient quality of life at community oncology settings","volume":"15","author":"Cohen","year":"2007","journal-title":"Support Care Cancer"},{"key":"2021122309230723200_B11","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.20230","article-title":"Incidence of chemotherapy-induced nausea and emesis after modern antiemetics","volume":"100","author":"Grunberg","year":"2004","journal-title":"Cancer"},{"key":"2021122309230723200_B12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00520-005-0788-5","article-title":"Incidence of chemotherapy-induced nausea and vomiting in Taiwan: Physicians\u2019 and nurses\u2019 estimation vs. patients\u2019 reported outcomes","volume":"13","author":"Liau","year":"2005","journal-title":"Support Care Cancer"},{"key":"2021122309230723200_B13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00520-007-0343-7","article-title":"A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre","volume":"16","author":"Molassiotis","year":"2008","journal-title":"Support Care Cancer"},{"key":"2021122309230723200_B14","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021122309230723200_B15","first-page":"1","article-title":"Emerging treatments in chemotherapy-induced nausea and vomiting","volume":"11","author":"Grunberg","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"2021122309230723200_B16","volume-title":"MASCC\/ESMO antiemetic guidelines"},{"key":"2021122309230723200_B17","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update [published correction appears in J Clin Oncol 2014;32:2117]","volume":"29","author":"Basch","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122309230723200_B18","volume-title":"NCCN clinical practice guidelines in oncology: Antiemesis. Version 1.2014"},{"key":"2021122309230723200_B19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0028-3908(96)00020-2","article-title":"Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets","volume":"35","author":"Tattersall","year":"1996","journal-title":"Neuropharmacology"},{"key":"2021122309230723200_B20","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1213\/ANE.0b013e31820886c3","article-title":"Rolapitant for the prevention of postoperative nausea and vomiting: A prospective, double-blinded, placebo-controlled randomized trial","volume":"112","author":"Gan","year":"2011","journal-title":"Anesth Analg"},{"key":"2021122309230723200_B21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/ACO.0b013e328301831c","article-title":"The role of neurokinin-1 receptor antagonists for the management of postoperative nausea and vomiting","volume":"21","author":"Apfel","year":"2008","journal-title":"Curr Opin Anaesthesiol"},{"key":"2021122309230723200_B22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/bja\/aep125","article-title":"Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting","volume":"103","author":"Diemunsch","year":"2009","journal-title":"Br J Anaesth"},{"key":"2021122309230723200_B23","first-page":"200","article-title":"Neurokinin 1 receptor antagonists\u2014between hope and disappointment [in German]","volume":"29","author":"Rost","year":"2006","journal-title":"Med Monatsschr Pharm"},{"key":"2021122309230723200_B24","first-page":"613","article-title":"Neurokinin 1 receptor antagonists\u2014current prospects","volume":"10","author":"Alvaro","year":"2007","journal-title":"Curr Opin Drug Discov Devel"},{"key":"2021122309230723200_B25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.biopsych.2005.07.013","article-title":"Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder","volume":"59","author":"Keller","year":"2006","journal-title":"Biol Psychiatry"},{"key":"2021122309230723200_B26","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.juro.2006.08.018","article-title":"Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence","volume":"176","author":"Green","year":"2006","journal-title":"J Urol"},{"key":"2021122309230723200_B27","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(12)70373-X","article-title":"Aprepitant for management of severe pruritus related to biological cancer treatments: A pilot study","volume":"13","author":"Santini","year":"2012","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"2021122309230723200_B28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/107327481201902s02","article-title":"Evolving treatment paradigms for chemotherapy-induced nausea and vomiting","volume":"19","author":"Wickham","year":"2012","journal-title":"Cancer Contr"},{"key":"2021122309230723200_B29","volume-title":"EMEND (aprepitant) [prescribing information]","year":"2013"},{"key":"2021122309230723200_B30","volume-title":"EMEND (fosaprepitant dimeglumine) [prescribing information]","year":"2013"},{"key":"2021122309230723200_B31","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/jnci\/djs335","article-title":"Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: A systematic review","volume":"104","author":"Santos","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"2021122309230723200_B32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40265-013-0019-1","article-title":"Management of chemotherapy-induced nausea and vomiting: Focus on newer agents and new uses for older agents","volume":"73","author":"Navari","year":"2013","journal-title":"Drugs"},{"key":"2021122309230723200_B33","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00520-011-1235-4","article-title":"Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: A multicenter, randomized, double-blind, active-controlled, two arm, parallel group study","volume":"20","author":"Hesketh","year":"2012","journal-title":"Support Care Cancer"},{"key":"2021122309230723200_B34","first-page":"375","article-title":"Casopitant: A novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting","volume":"5","author":"Ruhlmann","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"2021122309230723200_B35","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","article-title":"A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy","volume":"25","author":"Gralla","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122309230723200_B36","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","article-title":"Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: A randomized dose-ranging pivotal study","volume":"25","author":"Hesketh","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122309230723200_B37","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","article-title":"A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy","volume":"25","author":"Aapro","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122309230723200_B38","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0959-8049(00)00416-0","article-title":"Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis","volume":"37","author":"Cocquyt","year":"2001","journal-title":"Eur J Cancer"},{"key":"2021122309230723200_B39","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1200\/JCO.2001.19.6.1759","article-title":"Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone","volume":"19","author":"Campos","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122309230723200_B40","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1056\/NEJM199901213400304","article-title":"Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group","volume":"340","author":"Navari","year":"1999","journal-title":"N Engl J Med"},{"key":"2021122309230723200_B41","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2003.10.128","article-title":"Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy","volume":"21","author":"De Wit","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122309230723200_B42","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/cncr.11320","article-title":"Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting","volume":"97","author":"Chawla","year":"2003","journal-title":"Cancer"},{"key":"2021122309230723200_B43","first-page":"403","article-title":"Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: Palonosetron, dexamethasone, and aprepitant","volume":"4","author":"Grote","year":"2006","journal-title":"J Support Oncol"},{"key":"2021122309230723200_B44","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1002\/cncr.10516","article-title":"Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869","volume":"94","author":"Van Belle","year":"2002","journal-title":"Cancer"},{"key":"2021122309230723200_B45","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","article-title":"The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014the Aprepitant Protocol 052 Study Group","volume":"21","author":"Hesketh","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122309230723200_B46","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.11433","article-title":"Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America","volume":"97","author":"Poli-Bigelli","year":"2003","journal-title":"Cancer"},{"key":"2021122309230723200_B47","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/annonc\/mdl019","article-title":"Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment","volume":"17","author":"Schmoll","year":"2006","journal-title":"Ann Oncol"},{"key":"2021122309230723200_B48","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00520-009-0680-9","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study","volume":"18","author":"Rapoport","year":"2010","journal-title":"Support Care Cancer"},{"issue":"suppl 2","key":"2021122309230723200_B49","first-page":"vii69","article-title":"Aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapies in patients with gastrointestinal cancer","volume":"20","author":"Boice","year":"2009","journal-title":"Ann Oncol"},{"issue":"suppl 7","key":"2021122309230723200_B50","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1359-6349(09)71761-6","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapies in patients with lung cancer","volume":"7","author":"Rapoport","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021122309230723200_B51","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/0008-5472.SABCS-09-1116","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic (MEC) chemotherapy in patients with breast cancer","volume":"69","author":"Webb","year":"2009","journal-title":"Cancer Res"},{"key":"2021122309230723200_B52","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1185\/03007995.2014.925866","article-title":"Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: Effects of gender, age, and region","volume":"30","author":"Rapoport","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"2021122309230723200_B53","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy [published correction appears in J Clin Oncol 2005;23:5851]","volume":"23","author":"Warr","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122309230723200_B54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/JCO.2013.51.4547","article-title":"Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: A randomized double-blind study","volume":"32","author":"Roila","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122309230723200_B55","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/cncr.23364","article-title":"Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting","volume":"112","author":"Herrington","year":"2008","journal-title":"Cancer"},{"key":"2021122309230723200_B56","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00520-008-0535-9","article-title":"Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy","volume":"17","author":"Grunberg","year":"2009","journal-title":"Support Care Cancer"},{"key":"2021122309230723200_B57","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1177\/0091270007301800","article-title":"Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects","volume":"47","author":"Lasseter","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"2021122309230723200_B58","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/clpt.2012.62","article-title":"Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging","volume":"92","author":"Van Laere","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2021122309230723200_B59","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mds541","article-title":"Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: A multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"24","author":"Saito","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122309230723200_B60","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1200\/JCO.2010.31.7859","article-title":"Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol\u2014EASE","volume":"29","author":"Grunberg","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122309230723200_B61","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejca.2003.08.028","article-title":"The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: A combined analysis of two randomised, placebo-controlled phase III clinical trials","volume":"40","author":"De Wit","year":"2004","journal-title":"Eur J Cancer"},{"key":"2021122309230723200_B62","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s00520-013-2089-8","article-title":"Fosaprepitant-induced phlebitis: A focus on patients receiving doxorubicin\/cyclophosphamide therapy","volume":"22","author":"Leal","year":"2014","journal-title":"Support Care Cancer"},{"key":"2021122309230723200_B63","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1248\/bpb.b12-01086","article-title":"Interindividual variations in aprepitant plasma pharmacokinetics in cancer patients receiving cisplatin-based chemotherapy for the first time","volume":"36","author":"Motohashi","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"2021122309230723200_B64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00280-008-0713-y","article-title":"Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting","volume":"63","author":"Nakade","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309230723200_B65","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/00003088-200544060-00005","article-title":"Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant","volume":"44","author":"Bergman","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2021122309230723200_B66","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jgo.2012.08.008","article-title":"Efficacy of aprepitant among patients aged 65 and over receiving moderately to highly emetogenic chemotherapy: A meta-analysis of unpublished data from previously published studies","volume":"4","author":"Chapell","year":"2013","journal-title":"J Geriatr Oncol"},{"issue":"suppl","key":"2021122309230723200_B67","first-page":"S103","article-title":"Aprepitant for preventing chemotherapy induced nausea and vomiting","volume":"22","author":"Kang","year":"2014","journal-title":"Support Care Cancer"},{"key":"2021122309230723200_B68","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1177\/0091270011398243","article-title":"Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation","volume":"52","author":"Bubalo","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"2021122309230723200_B69","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1124\/dmd.30.7.814","article-title":"The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes","volume":"30","author":"Lindley","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"2021122309230723200_B70","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1365-2125.2010.03792.x","article-title":"The NK\u2081 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma","volume":"70","author":"Egerer","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"2021122309230723200_B71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbmt.2012.07.019","article-title":"Prevention of nausea and vomiting associated with stem cell transplant: Results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens","volume":"19","author":"Stiff","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122309230723200_B72","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1016\/j.transproceed.2011.08.010","article-title":"A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation","volume":"43","author":"Pielichowski","year":"2011","journal-title":"Transplant Proc"},{"key":"2021122309230723200_B73","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1007\/s00520-011-1341-3","article-title":"Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: A phase II trial","volume":"20","author":"Abidi","year":"2012","journal-title":"Support Care Cancer"},{"key":"2021122309230723200_B74","volume-title":"Drug interactions of aprepitant [slide presentation]"},{"key":"2021122309230723200_B75","volume-title":"Scientific discussion: This module reflects the initial scientific discussion for the approval of Emend"},{"key":"2021122309230723200_B76","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1093\/annonc\/mdq149","article-title":"Aprepitant: Drug-drug interactions in perspective","volume":"21","author":"Aapro","year":"2010","journal-title":"Ann Oncol"},{"key":"2021122309230723200_B77","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.ejca.2005.01.024","article-title":"The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials","volume":"41","author":"Warr","year":"2005","journal-title":"Eur J Cancer"},{"key":"2021122309230723200_B78","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/annonc\/mdt477","article-title":"Aprepitant does not alter prednisolone pharmacokinetics in patients treated with R-CHOP","volume":"25","author":"Maie","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122309230723200_B79","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00520-013-2043-9","article-title":"Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: A randomized, double-blind, placebo-controlled phase III trial","volume":"22","author":"Hu","year":"2014","journal-title":"Support Care Cancer"},{"key":"2021122309230723200_B80","first-page":"261","article-title":"China antiemetic guideline (2014 version)","volume":"19","year":"2014","journal-title":"Chin Clin Oncol"},{"key":"2021122309230723200_B81","first-page":"302","volume-title":"Practical guidelines on prophylaxis and treatment of nausea and vomiting in patients receiving chemo- and radiation therapy. Practical guidelines for treatment of malignant tumors. Practical guidelines for supportive care in oncology","author":"Poddubnaya","year":"2013"},{"key":"2021122309230723200_B82","volume-title":"Durand JF, Jovenin N. Prise en charge des nausees-vomissements chimio-induits NVCI"},{"key":"2021122309230723200_B83","first-page":"1","article-title":"[Latin-American guidelines for the management of emesis in oncology, haemato-oncology, and radiotherapy.]","volume":"3","author":"Ochoa-Carillo","year":"2011","journal-title":"Rev Bras Ciudad Paliat"},{"key":"2021122309230723200_B84","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122309230723200_B85","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JOP.2012.000816","article-title":"Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study","volume":"10","author":"Gilmore","year":"2014","journal-title":"J Oncol Pract"},{"key":"2021122309230723200_B86","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1470-2045(05)70284-9","article-title":"Antiemetic guidelines: Are they being used?","volume":"6","author":"Kaiser","year":"2005","journal-title":"Lancet Oncol"},{"key":"2021122309230723200_B87","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.jaad.2011.01.016","article-title":"Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues","volume":"66","author":"Torres","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2021122309230723200_B88","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/13543784.2013.813932","article-title":"Investigational drugs for pruritus","volume":"22","author":"Benecke","year":"2013","journal-title":"Expert Opin Investig Drugs"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2014-0229","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2014-0229","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/4\/450\/41868714\/oncolo_20_4_450.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/4\/450\/41868714\/oncolo_20_4_450.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T22:51:57Z","timestamp":1691535117000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/4\/450\/6399013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,20]]},"references-count":88,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,3,20]]},"published-print":{"date-parts":[[2015,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2014-0229","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,4,1]]},"published":{"date-parts":[[2015,3,20]]}}}